AIP
IKT icon

Ameritas Investment Partners’s Inhibikase Therapeutics IKT Stock Holding History

Ameritas Investment Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Hold
6,174
– – ﹤0.01% 2855
2025
Q4 		$12.7K Hold
6,174
– – ﹤0.01% 2835
2025
Q3 		$10K Hold
6,174
– – ﹤0.01% 2951
2025
Q2 		$12K Buy
+6,174
New +$12.1K ﹤0.01% 2913

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ameritas Investment Partners's IKT Position: Q1 2026 in Review

Ameritas Investment Partners held its Inhibikase Therapeutics (IKT) position steady in Q1 2026 at 6,174 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2855.

Ameritas Investment Partners first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. The position peaked at $12.7K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Ameritas Investment Partners held 6,174 shares of Inhibikase Therapeutics worth $10.4K as of Q1 2026.
  • Ameritas Investment Partners left its Inhibikase Therapeutics share count unchanged in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2855 holding.
  • Ameritas Investment Partners first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameritas Investment Partners's Inhibikase Therapeutics position peaked at $12.7K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.